Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience.
Antineoplastic therapies
CDK 4/6 inhibitors
Chemotherapy
Cutaneous adverse events
Hand-foot syndrome
Immune checkpoint inhibitors
Rash
Rosaceiform dermatitis
Target therapy
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
29 Feb 2024
29 Feb 2024
Historique:
received:
05
11
2023
accepted:
25
02
2024
medline:
1
3
2024
pubmed:
29
2
2024
entrez:
29
2
2024
Statut:
epublish
Résumé
Cutaneous adverse events can occur in patients treated with antineoplastic treatments, albeit their incidence has not been defined yet. The clinical presentation of CAEs related to anticancer treatments can vary. The purpose of our study is to characterize skin toxicities during oncological treatments, manage such adverse events to improve patients' quality of life, and ensure therapeutic adherence. We conducted a single-center prospective study which provided the enrollment of all patients referred to the Skin Toxicity Outpatient Clinic for the occurrence of cutaneous adverse events secondary to an ongoing antineoplastic treatment, between July 2021 and June 2023. We analyzed clinical features, and we described our therapeutic approach. Based on the type of drug assumed, chemotherapy-induced skin toxicity in 24 (38.7%) of the 62 evaluated patients, target therapies in 18 (29.0%), CDK4/6 cyclin inhibitors in 12 (19.4%), and immunotherapy in 6 (9.7%), while skin adverse events secondary to hormone therapy were seen in two patients. The most common cutaneous adverse event in our experience was rosaceiform rash of the face, followed by eczematous rash, hand-foot syndrome, and folliculitis. The present study is aimed at describing the variability and heterogeneity of clinical manifestations of different pharmacological classes used in oncological patients, as well as the different pathogenesis of skin damage. Chemotherapy very frequently causes skin toxicities that are often underestimated by clinicians. Their adequate recognition and optimal treatment lead to total recovery and allow better adhesion to chemotherapy.
Identifiants
pubmed: 38421520
doi: 10.1007/s00520-024-08407-4
pii: 10.1007/s00520-024-08407-4
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
200Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Payne AS, James WD, Weiss RB (2006) Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 33(1):86–97
doi: 10.1053/j.seminoncol.2005.11.004
pubmed: 16473647
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245
doi: 10.1038/clpt.1981.154
pubmed: 7249508
Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A et al (2023) Cyclin-dependent kinase 4/6 inhibitors and dermatologic adverse events: results from the EADV task force “Dermatology for Cancer Patients” International Study. Cancers 15(14):3658
doi: 10.3390/cancers15143658
pubmed: 37509319
pmcid: 10377938
Markman M (2003) Managing taxane toxicities. Support Care Cancer 11(3):144–147
doi: 10.1007/s00520-002-0405-9
pubmed: 12618923
Cortes JE, Pazdur R (1995) Docetaxel. JCO 13(10):2643–2655
doi: 10.1200/JCO.1995.13.10.2643
Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26(5):427–443
doi: 10.1684/ejd.2016.2833
pubmed: 27550571
pmcid: 5526115
Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332(15):1004–14. https://doi.org/10.1056/NEJM199504133321507
Gelmon K (1994) The taxoids: paclitaxel and docetaxel. The Lancet 344(8932):1267–1272
doi: 10.1016/S0140-6736(94)90754-4
Wahab A, Khakwani M, Ehsan H, Bellam N (2020) Paclitaxel-induced palmar-plantar erythrodysesthesia. Cureus 12(11):e11507. https://doi.org/10.7759/cureus.11507
Nikolaou V, Syrigos K, Saif MW (2016) Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 15(12):1625–1633
doi: 10.1080/14740338.2016.1238067
pubmed: 27718746
Merlo G, Cozzani E, Canale F, Miglino M, Gambella M, Burlando M et al (2019) Cutaneous manifestations of hematologic malignancies the experience of an Italian dermatology department. Hematol Oncol 37(3):285–290
doi: 10.1002/hon.2569
pubmed: 30485475
Blum AE, Burgin S (2021) Eczematous drug eruptions. Am J Clin Dermatol 22(3):349–366
doi: 10.1007/s40257-021-00586-8
pubmed: 33587283
Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B et al (2018) Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncol 84:46–51
doi: 10.1016/j.oraloncology.2018.06.028
pubmed: 30115475
Van Zuuren EJ, Arents BWM, Van Der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J (2021) Rosacea: new concepts in classification and treatment. Am J Clin Dermatol 22(4):457–465
doi: 10.1007/s40257-021-00595-7
pubmed: 33759078
pmcid: 8200341
Tziotzios C, Lee JYW, Brier T, Saito R, Hsu CK, Bhargava K et al (2018) Lichen planus and lichenoid dermatoses. J Am Acad Dermatol 79(5):789–804
doi: 10.1016/j.jaad.2018.02.010
pubmed: 30318136
Solimani F, Forchhammer S, Schloegl A, Ghoreschi K, Meier K (2021) Lichen planus – a clinical guide. J Deutsche Derma Gesell 19(6):864–882
Caiado J, Picard M (2014) Diagnostic tools for hypersensitivity to platinum drugs and taxanes: skin testing, specific IgE, and mast cell/basophil mediators. Curr Allergy Asthma Rep 14(8):451
doi: 10.1007/s11882-014-0451-7
pubmed: 24951237
Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144(6):1169–1176
doi: 10.1046/j.1365-2133.2001.04226.x
pubmed: 11422037
Lynch TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME (2007) Epidermal growth factor receptor inhibitor–associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12(5):610–621
doi: 10.1634/theoncologist.12-5-610
pubmed: 17522250
Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6(10):803–812
doi: 10.1038/nrc1970
pubmed: 16990857
Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E (2018) Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer 17(2):85–96
doi: 10.1016/j.clcc.2017.12.004
pubmed: 29576427
Owczarek W, Słowińska M, Lesiak A, Ciążyńska M, Maciąg A, Paluchowska E et al (2017) The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors. pdia 5:418–28
doi: 10.5114/ada.2017.71106
Sibaud V, Sollena P (2023) Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice. Ann Dermatol Venereol 150(3):208–212
doi: 10.1016/j.annder.2022.11.013
pubmed: 37586898
Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR et al (2017) Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158–176
doi: 10.1111/cup.12858
pubmed: 27859479
Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ et al (2021) Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res Treat 185(1):247–253
doi: 10.1007/s10549-020-05914-w
pubmed: 32914354
Nayar N, Briscoe K, Fernandez PP (2016) Toxic epidermal necrolysis–like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother 39(3):149–152
doi: 10.1097/CJI.0000000000000112
pubmed: 26938948
Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH et al (2018) Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. CMAR 10:1259–1273
doi: 10.2147/CMAR.S163391
Kim YJ, Cohen PR (2020) Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. Dermatol Ther (Heidelb) 10(1):221–229
doi: 10.1007/s13555-020-00353-3
pubmed: 31965545